PatternsRadar
Sign in

SHILPAMEDShilpa Medicare Limited

NSE
Full chart
1,073.70INR+42.50 (+4.12%)Close · 6 Oct 2026
5 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹21,000 CrMarket cap
70.6P/E (TTM)
47.6%Delivery

Filings & corporate actions

69 results filed
CSV
Next results · Q2 FY27
Expected 30 Oct 2026 – 14 Nov 2026
Estimate: filed 30–45 days after quarter end, last 5 times
Dividend
₹0.60 per share · last 4 Sept 2026
2026
  • 4 SeptdividendDividend · ₹0.60 per share+0.8%
  • 5 AugresultsResults · Q1 FY27 · consolidated and standalone+12.0%NSE
  • 13 JulshareholdingShareholding · 30 Jun 2026+0.5%NSE
  • 22 MayresultsResults · Q4 FY26 · consolidated and standalone+4.5%NSE
  • 9 AprshareholdingShareholding · 31 Mar 2026+3.8%NSE
  • 6 FebresultsResults · Q3 FY26 · consolidated and standalone+5.3%NSE
  • 12 JanshareholdingShareholding · 31 Dec 2025-1.3%NSE

Reaction to results · all yearsrose on day 0 in 31 of 67 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY275 Aug 2026+12.0%+24.9%+44.0%28.2×
Q4 FY2622 May 2026+4.5%+5.5%+20.6%4.8×
Q3 FY266 Feb 2026+5.3%+4.3%+7.2%4.0×
Q2 FY2613 Nov 2025-2.8%-10.2%-15.2%1.0×
Q1 FY2613 Aug 2025+0.3%-6.0%-9.0%2.2×
Q4 FY2526 May 2025-1.8%-1.7%-2.9%3.5×
Q3 FY2511 Feb 2025-4.1%-7.3%-6.9%1.1×
Q2 FY2514 Nov 2024+5.9%+8.8%-1.7%4.7×
Q1 FY259 Aug 2024-0.6%-2.5%+17.8%1.1×
Q4 FY2424 May 2024-1.5%-3.5%+17.8%1.0×
Q3 FY249 Feb 2024-4.0%-1.1%+10.0%3.4×
Q2 FY2410 Nov 2023-0.5%-1.8%-1.3%0.5×
Q1 FY2410 Aug 2023+0.3%+6.9%+5.9%0.5×
Q4 FY2326 May 2023-2.9%-3.2%+1.9%1.7×
Q3 FY2315 Feb 2023-0.2%+16.4%+1.3%1.1×
Q2 FY2312 Nov 2022-2.5%-4.5%-1.1%2.9×
Q1 FY2312 Aug 2022-1.2%-1.5%-2.2%1.1×
Q4 FY2224 May 2022-4.7%-3.9%-7.7%1.1×
Q3 FY229 Feb 2022-5.1%-6.0%-13.3%1.6×
Q2 FY2230 Oct 2021+2.2%+0.5%-3.2%1.0×
Q1 FY2214 Aug 2021-4.9%-5.3%-1.7%0.8×
Q4 FY211 Jun 2021-4.6%+9.6%+6.4%0.9×
Q3 FY2113 Feb 2021-1.1%-14.9%-18.5%3.7×
Q2 FY213 Nov 2020+1.6%+0.1%+9.9%0.7×
Q1 FY218 Aug 2020+11.0%+3.4%-10.1%6.2×
Q4 FY2018 Jun 2020-1.6%-6.8%-1.9%0.3×
Q3 FY2011 Feb 2020+10.0%+10.3%-1.3%3.5×
Q2 FY2010 Nov 2019+2.1%-7.9%-10.5%3.5×
Q1 FY2014 Aug 2019-16.9%-24.1%-20.4%5.3×
Q4 FY1928 May 2019-5.8%-7.6%-9.4%4.8×
Q3 FY1913 Feb 2019-1.3%-1.9%+2.3%0.4×
Q2 FY1922 Nov 2018-0.6%-1.0%0.0%0.3×
Q1 FY1931 Aug 2018+0.8%-1.9%-18.4%0.6×
Q4 FY1826 Jun 2018-1.8%-4.6%-3.5%0.5×
Q3 FY1822 Feb 2018+1.7%-7.7%+9.1%0.7×
Q2 FY1821 Nov 2017+4.3%+6.8%+0.4%1.3×
Q1 FY1821 Aug 20170.0%+9.7%+4.9%0.4×
Q4 FY1715 Jun 2017-0.1%-0.9%+6.3%0.2×
Q3 FY1715 Feb 2017-2.5%-0.5%-0.7%2.3×
Q2 FY1729 Nov 2016+4.9%-1.9%+5.4%1.6×
Q1 FY173 Oct 2016+11.2%+6.7%+8.8%10.8×
Q4 FY1630 May 2016+5.7%+3.9%+10.4%3.2×
Q3 FY1613 Feb 2016+3.7%+2.7%+6.0%1.0×
Q2 FY169 Nov 2015+2.6%+13.3%-4.9%1.9×
Q1 FY1610 Aug 2015+1.7%+0.2%-13.9%2.6×
Q4 FY154 Jun 2015-0.5%-6.1%-5.5%0.2×
Q3 FY1518 Feb 2015-1.9%-9.4%+11.1%0.5×
Q2 FY1522 Nov 20140.0%-2.5%+12.7%0.5×
Q1 FY1520 Aug 2014+1.1%-1.4%+2.1%2.8×
Q4 FY1429 May 2014+1.7%0.0%+0.1%3.9×
Q3 FY1411 Feb 20140.0%+6.3%+8.2%2.6×
Q2 FY1412 Nov 2013+1.2%+4.1%+12.4%1.2×
Q1 FY1416 Aug 2013+2.6%+0.8%-0.3%1.2×
Q4 FY136 Jun 2013+1.1%-0.9%+0.4%0.2×
Q3 FY1312 Feb 2013+1.9%+3.9%-1.2%1.5×
Q2 FY137 Nov 2012+1.4%+0.9%+5.6%1.1×
Q1 FY1313 Aug 2012+1.0%+10.2%+8.6%0.7×
Q4 FY1216 May 2012-0.6%+13.4%+5.1%0.1×
Q3 FY1210 Feb 2012-5.1%-3.5%+0.3%1.4×
Q2 FY1218 Nov 2011+2.6%-5.7%-23.0%0.2×
Q1 FY1219 Aug 2011+1.3%+3.6%+9.7%0.4×
Q4 FY1112 May 2011-0.1%-1.0%-1.2%1.2×
Q3 FY1128 Jan 2011-2.5%-2.4%-2.9%0.5×
Q2 FY1127 Oct 2010-3.3%-9.7%-21.8%2.1×
Q1 FY1128 Jul 2010-0.7%+8.0%+3.6%2.5×
Q4 FY1029 Apr 2010+3.1%-1.3%-12.5%0.2×
Q3 FY1025 Jan 2010-0.8%-7.9%-9.3%0.3×
Average+0.3%-0.1%+0.3%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+44.9%
Profit YoY+115.2%
Interest cost YoY—
Revenue QoQ+6.6%
Profit QoQ-6.4%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open1,028.10
Day range1,026.10 – 1,079.90
52-week range259.50 – 1,095.00
From 52w high-1.9%
RSI (14)65.3
ATR (14)49.26
Volume5.87L
Avg volume (20D)9.18L
Rel volume0.64×
Volatility (1Y)42.1%
Turnover₹63.0Cr
SMA 50 / 200875.38 / 530.49

Delivery percentage

Latest · 6 Oct 202647.6%
20-day avg40.8%
1-year avg47.1%
Percentile (own history)56th
Range3.8–100.0%
Sessions1,731

Over the last 20 sessions SHILPAMED settled 40.8% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 47.1%, so recent sessions are running 6.2 points lower than usual. The latest session ranks higher than 56% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+4.12%+4.73%+12.29%+79.01%+176.09%+178.23%

Valuation

CSV
Market cap₹21,000 Cr
P/E (TTM)70.6
EPS (TTM)15.20
Shares outstanding1.00L
Listed3 Dec 2009

Ownership

CSV
Promoter40.13%
Promoter Δ QoQ0.00 pp
Public59.87%
FII11.38%
DII8.05%
Pledged8.73%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)370.0409.7437.0465.8
YoY chg——+32.1%+44.9%
Net profit (₹ Cr)44.144.6107.8100.9
YoY chg——+642.9%+115.2%
Net margin11.9%10.9%24.7%21.7%
EPS1.132.365.515.16

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 40.13% · public 59.87%
30 Sept 2021: promoter 53.25%12 Nov 2021: promoter 50.01%31 Dec 2021: promoter 50.01%31 Mar 2022: promoter 50.01%30 Jun 2022: promoter 50.01%30 Sept 2022: promoter 50.01%31 Dec 2022: promoter 50.01%31 Mar 2023: promoter 50.01%30 Jun 2023: promoter 50.01%30 Sept 2023: promoter 50.01%31 Dec 2023: promoter 50.01%31 Mar 2024: promoter 50.01%13 Apr 2024: promoter 44.39%30 Jun 2024: promoter 44.39%30 Sept 2024: promoter 44.33%31 Dec 2024: promoter 44.23%31 Mar 2025: promoter 44.23%30 Jun 2025: promoter 44.23%30 Sept 2025: promoter 44.23%31 Dec 2025: promoter 40.13%31 Mar 2026: promoter 40.13%30 Jun 2026: promoter 40.13%
2021-092026-06
  • Promoter
  • Public and others
Promoter
40.13%
Public
59.87%
Promoter change
0.00 pp
Filed
13 Jul 2026
FII
11.38%
DII
8.05%
Promoter pledged
8.73%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations313.0286.5291.7292.5343.8319.3330.8321.5370.0409.7437.0465.8
Other income1.82.22.59.45.01.17.66.41.80.81.73.1
Total income314.8288.7294.2302.0348.8320.4338.4327.8371.7410.5438.7468.9
Total expenses303.7273.5272.5269.8311.6279.2297.3277.5307.2336.5361.6376.8
└ Finance costs23.226.224.223.725.611.714.518.815.710.713.712.1
└ Depreciation27.826.726.627.128.328.828.828.929.830.430.635.2
Profit before tax11.115.227.932.237.241.313.050.364.561.2120.592.1
Tax expense7.69.53.214.618.89.80.82.720.416.312.7(2.8)
Net profit1.64.724.514.117.931.814.546.944.144.6107.8100.9
EPS0.100.271.410.730.921.630.742.401.132.365.515.16
Net margin0.50%1.64%8.40%4.81%5.22%9.95%4.39%14.59%11.91%10.88%24.67%21.66%
PBT margin3.54%5.32%9.55%11.01%10.81%12.92%3.92%15.65%17.45%14.94%27.56%19.77%
Tax rate68.57%62.13%11.53%45.40%50.67%23.81%5.90%5.36%31.55%26.58%10.51%-3.07%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.

SHILPAMED at a glance

  • SHILPAMED closed at ₹1,073.7 on 6 Oct 2026, +4.12% on the day, +178.2% over one year, 1.9% below its 52-week high of ₹1,095.
  • Delivery was 47.6% of traded quantity on 6 Oct 2026, the 56th percentile of its own 1,731 sessions with a reading (20-session average 40.8%, 1-year average 47.1%).
  • Market capitalisation is ₹21,000 crore at a trailing P/E of 70.6 (trailing EPS ₹15.2).
  • Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹466 crore (+44.9% year on year), net profit ₹101 crore (+115.2%); the price moved +12.0% on the first session after.
  • Promoters held 40.13% at 30 Jun 2026, unchanged on the previous filing, with 8.73% of promoter shares pledged.
  • Q2 FY27 results are expected between 30 Oct 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE790G01031
SeriesEQ
Listed3 Dec 2009
History from3 Dec 2009
Sessions4,172
Turnover rank#318

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE